ストックスクリーナーアプリを入手
17.34
3.90%
0.665
前日終値:
$16.68
開ける：
$16.798
24時間の取引高:
4.99M
Relative Volume:
0.47
時価総額：
$20.19B
収益：
$14.57B
当期純損益:
$-296.50M
株価収益率:
-66.97
EPS:
-0.259
ネットキャッシュフロー:
$1.64B
1週間 パフォーマンス:
+6.06%
1か月 パフォーマンス:
+8.04%
6か月 パフォーマンス:
+34.76%
1年 パフォーマンス:
+90.86%
1日の値動き範囲:
$16.65
$17.38
1週間の範囲:
$15.95
$17.38
52週間の値動き範囲:
$8.625
$17.53
Viatris Inc Stock (VTRS) Company Profile
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.34 | 19.42B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
16.70 | 52.53B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.11 | 42.94B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.09 | 36.75B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.24 | 31.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
528.31 | 22.57B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-09 | アップグレード | UBS | Neutral → Buy |
| 2026-01-16 | アップグレード | Argus | Hold → Buy |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-06-06 | 開始されました | Goldman | Neutral |
| 2024-07-19 | 再開されました | Jefferies | Buy |
| 2023-10-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2023-04-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-02-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-10 | アップグレード | UBS | Sell → Neutral |
| 2022-11-08 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2022-06-14 | 開始されました | UBS | Sell |
| 2022-05-10 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 開始されました | Citigroup | Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 開始されました | Argus | Hold |
| 2020-12-14 | 開始されました | Bernstein | Mkt Perform |
すべてを表示
Viatris Inc (VTRS) 最新ニュース
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Looks to New Launches and Cost Savings for Long-Term Growth - Morningstar
XS332542958 Bond Profile — Key Metrics - TradingView
ETFs Investing in Viatris, Inc. Stocks - TradingView
Mylan to sell up to $363 million stake in India’s Biocon, term sheet shows - WTVB
Viatris unit Mylan plans to sell stake worth up to $363 million in Biocon - Business Standard
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows - Reuters
(VTRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viatris shares break six-session winning streak - MSN
BofA Securities Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $14 - Moomoo
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance
Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS) - Sahm
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - AOL.com
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move? - Yahoo Finance
Viatris Q1 2026 slides: earnings beat drives shares higher - Investing.com
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results - Yahoo Finance
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now - Insider Monkey
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. Class Action: The Gross Law Firm Reminds Viatris In - GuruFocus
VTRS Stock Price and Chart — NASDAQ:VTRS - TradingView
A Look at Viatris Inc (VTRS) After 3.1% Gain -- GF Value $11.02 vs Price $16.70 - GuruFocus
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris (VTRS) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Viatris Refinances $247.7 Million Term Loan - Moomoo
VTRSViatris Inc Dividends - Finviz
Form 4 Viatris Inc For: 1 July By Investing.com - Investing.com Canada
Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as fees - Stock Titan
Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees - Stock Titan
Viatris to Report Second-Quarter 2026 Financial Results on Augus - GuruFocus
ViatrisEnters Amended And Restated Term Loan Credit Agreement On July 1, 2026SEC Filing - TradingView
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility - TradingView
Viatris (NASDAQ: VTRS) signs ¥40B three-year unsecured term loan deal - Stock Titan
Viatris Inc Enters Into Amended and Restated Term Loan Credit Agreement for JPY 40,000,000,000 Senior Unsecured Term Loan Facility - marketscreener.com
Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025Contact Levi & Korsinsky - The National Law Review
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205 - simplywall.st
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Securities Fraud Class Action Filed Against Viatris Inc. (VTRS) Levi & Korsinsky Reminds Investors of June 3, 2025 - The National Law Review
Viatris reports positive phase 3 results for IgAN drug in Japan By Investing.com - Investing.com India
(VTRS) Risk Channels and Responsive Allocation - Stock Traders Daily
How is Viatris’ stock performance compared to other healthcare stocks? - MSN
Viatris reports positive Japanese phase 3 results for Nefecon in IgAN - MSN
Viatris reports positive phase 3 results for IgAN drug in Japan - Investing.com South Africa
Viatris' VR-205 Meets Primary, Key Secondary Endpoints in Japanese Phase 3 Trial in Kidney Disease - marketscreener.com
Viatris (VTRS) Reports Positive Phase 3 Trial Results for VR-205 - GuruFocus
Viatris kidney drug VR-205 cut protein in urine 33.75% in Japan - Stock Titan
Viatris Inc. (VTRS) Stock Analysis: Exploring a 9% Upside Potential Amid Diverse Healthcare Offerings - DirectorsTalk Interviews
Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – VTRS - The National Law Review
Viatris Inc (VTRS) 財務データ
収益
当期純利益
現金流量
EPS
1.15%
1.63%
大文字化:
|
ボリューム (24 時間):